Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BMM vs HCM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HCM Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–0 Matrix Metrics)

HCM Overall Winner 6-Pillar Tally: BMM 0 – 5 HCM (1 Tie) Matrix Metrics: BMM 0 – 8 HCM

As of Nov 20, 2026, HUTCHMED (China) Limited (HCM) is the stronger overall head-to-head candidate over BMM (BMM) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMM carries a Unified Composite Score of 38.2/100 (SELL) at $2.50 (N/M Forward P/E, N/A operating margin), whereas HCM carries 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin).

  • Defensive Composite Rating Caution: Although HCM compares more favorably head-to-head, both BMM (38.2/100 SELL) and HCM (38.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: BMM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.8); meanwhile HCM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMM vs HCM
BMM US Equity
BMM
Institutional Equity
$2.50
-8.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.19β · 100% Vol
Unified Composite Score
38.2 / 100 SELL
Tech 25.0 Fund 39.0 Flow 50.0 Mom 34.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.9%), weak momentum, RSI 26
RSI-14: 25.8 · SMA20: $3.40 · SMA50: $4.28
HCM NASDAQ Head-to-Head Winner
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
$13.22
-1.71% 1D
Market Cap $2.3B
TTM Revenue $549M
Forward P/E N/M
Beta / 30D Vol 0.64β · 45% Vol
Unified Composite Score
38.1 / 100 SELL
Tech 31.0 Fund 44.0 Flow 50.0 Mom 56.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.5 · SMA20: $14.15 · SMA50: $14.11

6-Pillar Scorecard Institutional Category Breakdown (BMM 0 – 5 HCM)

Columns: Metric · BMM · HCM
1. Valuation Multiples HCM
Forward P/E N/M N/M
Trailing P/E N/M 134.0x
PEG Ratio N/M N/M
EV / Revenue N/M 4.2x
2. Growth & Scale HCM
Revenue Growth (YoY) N/A +0.2%
Earnings Growth (YoY) N/A -96.5%
TTM Revenue (USD) N/A $549M
Market Cap N/A $2.3B
3. Profitability & Quality HCM
Gross Margin N/A 13.3%
Operating Margin N/A -6.3%
Net Profit Margin N/A 3.3%
Return on Equity (ROE) N/A 1.5%
4. Balance Sheet & Cash Flow HCM
Cash Generation (TTM) N/A -$21M EBITDA
Cash Flow Margin N/A -3.7% EBITDA Mgn
Net Cash / Leverage N/A ROE $7.25 Book/Sh · 1.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 82.7% (73rd %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat HCM
OpEx & R&D Intensity N/A 19.6% of Rev ($108M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMM (0) vs HCM (8)
Institutional Metric BMM HCM Criterion Row Edge
Market Capitalization
Scale
N/A $2.3B Larger Scale HCM
Trailing P/E Ratio
Valuation
N/M 134.0x Lower Multiple HCM
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.2% Higher Growth HCM
Operating Margin (TTM)
Profitability
N/A -6.3% Higher Margin HCM
Net Profit Margin
Profitability
N/A 3.3% Higher Margin HCM
Return on Equity (ROE)
Capital Efficiency
N/A 1.5% Higher ROE HCM
52-Week Range Position
Momentum
0% ($2–$9) 53% ($10–$16) Stronger Trend HCM
Beta / 30D Volatility
Risk Regime
2.19β · 100% Vol 0.64β · 45% Vol Lower Realized Risk HCM
Unified Institutional Score
Composite Signal
38.2 / 100 (SELL) 38.1 / 100 (SELL) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
N/A $549M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 13.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$21M EBITDA ($7.25 Book/Sh · 1.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HCM +29.13 pp
BMM: -36.55% · HCM: -7.42%
3M Horizon HCM +61.46 pp
BMM: -52.92% · HCM: +8.54%
6M Horizon HCM +75.25 pp
BMM: -64.99% · HCM: +10.26%
1Y Horizon HCM +29.6 pp
BMM: -44.69% · HCM: -15.09%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMM vs HCM. Trailing 12-month operating profitability (BMM N/A vs HCM -6.3%) and valuation multiples (BMM N/M vs HCM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BMM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
HCM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$549M
Gross Margin13.3%
Op. Margin-6.3%
ROE / Fwd P/E1.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HCM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 82.7%
IV Percentile 73rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMM Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
HCM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.3B market capitalization and -6.3% operating margin.
OpEx & R&D Reinvestment 19.6% of Rev ($108M)
90D Engineering Disclosures 0 Published

Investor FAQ BMM vs HCM Key Questions & Quantitative Answers

As of Nov 20, 2026, HUTCHMED (China) Limited (HCM) is the stronger overall head-to-head candidate over BMM (BMM) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMM carries a Unified Composite Score of 38.2/100 (SELL) at $2.50 (N/M Forward P/E, N/A operating margin), whereas HCM carries 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin). Defensive Composite Rating Caution: Although HCM compares more favorably head-to-head, both BMM (38.2/100 SELL) and HCM (38.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: BMM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.8); meanwhile HCM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HCM leads the Growth & Scale pillar: BMM posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with HCM at +0.2% YoY revenue growth and -96.5% YoY earnings growth on $549M TTM revenue (13.3% gross margin, -6.3% operating margin). On trailing 12-month operating scale, BMM generates N/A in USD-normalized revenue versus $549M for HCM. In operating R&D and SG&A reinvestment, BMM deploys N/A (0 90-day corporate R&D disclosures) versus 19.6% of Rev ($108M) (0 disclosures) for HCM.

HCM screens cheaper on headline valuation multiples. BMM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HCM trades at N/M Forward P/E, 134.0x Trailing P/E, N/M PEG, and 4.2x EV/Revenue (-3.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMM (N/A ROE) versus HCM (1.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BMM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.19β · 100% Vol realized risk). By comparison, HCM carries 82.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.64β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.